Drugs / LSC2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03549299 | Jul 2019 → Sep 2023 | limbal stem cell deficiency | RHEACELL GmbH & Co. KG | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LSC2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03549299 ↗ |
| Modality | Cell therapy | “The allogeneic investigational product LSC2 contains ABCB5-positive limbal stem cells” NCT03549299 ↗ |
| Route | Topical | “the IMP topically administered on the target eye” NCT03549299 ↗ |